Jaguar Health, Inc.
10.8.2021 14:33:12 CEST | ACCESS Newswire | Press release
- Registration link for webcast appears below
- Company plans to file Q2 2021 10-Q on August 13, 2021
- Jaguar kicks off educational awareness contest in honor of African Traditional Medicine Day
SAN FRANCISCO, CA / ACCESWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a webcast on Friday, August 13, 2021 at 8:30 a.m. Eastern Time to review second-quarter 2021 financials and provide business updates.
Participation Instructions for Webcast
When: Friday, August 13, 2021 at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
Jaguar Kicks Off Educational Awareness Contest in Honor of African Traditional Medicine Day
Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A., are deeply committed to recognizing and honoring the knowledge and expertise of Indigenous healers who first discovered the medicinal properties of specific plants. African Traditional Medicine Day, celebrated each year on August 31st, was established by the World Health Organization on August 31, 2000 to acknowledge the contribution African traditional medicine has made to human health for centuries. Jaguar is delighted to focus on African traditional medicine for this fourth educational awareness contest in the Company's series. The winner will receive a signed and framed print (4/25) of the original painting below of a jaguar by Anthony J. Conte. The painting was inspired by a photograph of a jaguar taken by Christopher Scharf in the Cockscomb Basin Wildlife Sanctuary & Jaguar Preserve in Belize.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.The winner will be chosen at random from the pool of contest participants who correctly answer all or most questions in the multiple-choice entry form. Entries must be received by 9:00 a.m. US Eastern Time on August 31, 2021. No fee is required to enter the contest. Additional contest terms and conditions apply. Click here to enter and for contest terms and conditions.
Stay tuned to the "Jaguar Health Community" page on Instagram (https://www.instagram.com/jaguarhealthcommunity/) to view the contest winner's name, view the answers to the contest questions, and learn about future contests.
Anthony J. Conte, 90, is an accomplished painter, published journalist, a lifelong outdoor enthusiast, and an accomplished figure skater who began skating at the age of 67. His oil paintings have been auctioned at fundraising events for conservation groups such as the Atlantic Salmon Federation and Wild Sheep Foundation. "Eye, Jaguar" is his first painting of a rainforest-dwelling mammal, created for and gifted to Jaguar Health, Inc.
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the Company's expectation that an investor webcast will take place August 13, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/659052/Jaguar-Health-to-Host-Investor-Webcast-Friday-August-13th-at-830-AM-Eastern-Time-Regarding-Q2-2021-Financials-Business-Updates
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Supported by U.S. Polo Assn., the 2026 U.S. Open Women's Polo Championship(R) Concludes with Victory Eastern Hay the Champion17.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL / ACCESS Newswire / February 17, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the 2026 U.S. Open Women's Polo Championship®, which concluded on February 15 at the USPA National Polo Center (NPC) in Wellington, Florida, on the iconic U.S. Polo Assn. Stadium Field. Widely regarded as the most prestigious women's polo tournament in the United States, the championship brought together the sport's top athletes for three weeks of elite competition at the heart of American polo.1. Victory Eastern Hay proudly displaying their trophy as winner of the 2026 U.S. Open Women's Polo Championship at the USPA National Polo Center 2. Victory Eastern Hay Team on horseback (#1 Rebecca Schmeits, #2 Aspen Tinto, #3 Hazel Jackson, #4 Milly Hine) at the 2026 U.S. Open Women's Polo Championship 3. La Dolfina Team presents a donation to their charity of choice, Polo Players Support Group, provided by U.S. Polo Assn., at th
Camino Intercepts High-Grade Copper with 83.5m at 0.94% Cu including 7.1m at 2.13% Cu at Los Chapitos, Peru17.2.2026 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company")is pleased to announce the exploration results from Phase 1 of the recent drilling campaign at its Los Chapitos copper project ("Los Chapitos" or the "Project") in Peru. This news release reports the results from eight drill holes completed along the Diva trend corridor, where drilling activities focused on several targets with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. Los Chapitos is Camino's second copper project with partner Nittetsu Mining Co, Ltd. ("Nittetsu"), who is completing a 35% earn-in interest in Los Chapitos after investing CAD $10 million and after the completion of Phase 2 of the current drilling campaign (see news release dated June 14, 2023). Camino is also advancing its Puquios Copper Project in Chile with Nittetsu Mining towards mine cons
Datavault AI Updates Revenue Estimates by Approximately 30% at $38M to $40M17.2.2026 12:00:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / February 17, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today announced its updated preliminary (unaudited) fiscal year 2025 revenue is estimated to be $38 to $40 million, exceeding its prior estimate of $30 million by up to 33%. At its midpoint, estimated FY-25 revenue represents approximately 1,300% growth year-over-year The Company attributed this revenue growth to its customer tech-licensing fees, and its Data Science Group's tokenization and monetization services. Further, Datavault AI reaffirmed its anticipated FY-26 revenue of $200 million, which, if achieved, would represent a year-over-year increase of 400% to 440%. KEY FINANCIAL METRICS FY 2025 (Preliminary, Unaudited): Estimated Revenue: $38-$40 million Prior Estimate: $30 million Incremental Change: +$8-$10 million (+27% to +33%) Midpoint:
Skymantics Europe Leverages DataGenesis to Power Next-Gen European Digital Twins with High-Fidelity Synthetic Populations16.2.2026 11:00:00 CET | Press release
ZARAGOZA, ES / ACCESS Newswire / February 16, 2026 / Skymantics Europe's DataGenesis platform supports the evolution of European Digital Twins. By providing high-accuracy, high-resolution synthetic population datasets, DataGenesis enables the simulation of complex demographic, socioeconomic, and health attributes, allowing for precise future scenario planning and more resilient policy-making across the continent. As Europe moves into a more sophisticated phase of digital modeling, the need to integrate the "human dimension" into Earth-system and urban models is paramount. DataGenesis addresses this by generating "digital twins" of populations that maintain the statistical integrity and multidimensional complexity of real-world communities-without utilizing or exposing sensitive personal information. Integrating Human Dynamics into Digital Ecosystems Skymantics' DataGenesis platform bridges the gap between environmental data and societal impact. Its mature model-based AI approach provid
GA-ASI Achieves New Milestone With Semi-Autonomous CCA Flight12.2.2026 21:55:00 CET | Press release
YFQ-42A Uncrewed Fighter Jet Executes Mission Autonomy Test SAN DIEGO, CA / ACCESS Newswire / February 12, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) passed a new milestone this month, successfully integrating 3rd-party mission autonomy into the YFQ-42A Collaborative Combat Aircraft to conduct its first semi-autonomous airborne mission. For this test, GA-ASI used mission autonomy software supplied by Collins Aerospace, an RTX business, to fly the new YFQ-42A CCA, designed and developed by GA-ASI for the U.S. Air Force. The Sidekick Collaborative Mission Autonomy software was seamlessly integrated with the YFQ-42A's flight control system, utilizing the Autonomy Government Reference Architecture (A-GRA). The integration enabled robust and reliable data exchange between the autonomy software and the aircraft's mission systems, ensuring precise execution of mission autonomy commands. During the recent testing, autonomy mode was activated via the Ground Station Console (GSC)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom